An exploration of the optimal combination chemotherapy regimen based on neoadjuvant therapy containing pyrotinib for HER2-positive breast cancer: A multicenter real-world study

Background: The combination of pyrotinib (Py) with cytotoxic agents proved to be effective in early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). However, the optimal chemotherapy regimen is unknown. This study attempts to explore it from real-world research data. Meth...

Descripción completa

Detalles Bibliográficos

Autores principales:	Shan Wang, Zining Jin, Zhaohui Li, Guolian Zhu, Bin Liu, Dianlong Zhang, Shuhong Tang, Fan Yao, Jian Wen, Yi Zhao, Xiaolan Wang, Feng Jin, Jia Wang
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Elsevier 2025-01-01
Colección:	Translational Oncology
Materias:	Pyrotinib Neoadjuvant therapy Breast cancer
Acceso en línea:	http://www.sciencedirect.com/science/article/pii/S1936523324002997
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!